Bafna Pharmaceuticals Reports Revenue Growth and Profit Decline in Q2 FY2026

Bafna Pharmaceuticals Limited , a Chennai-based pharmaceutical company, has released its unaudited financial results for the second quarter and half-year ended September 30, 2025, showcasing a mixed performance with revenue growth and a slight decline in profitability.

Financial Highlights

The company reported revenue from operations of INR 3,546.82 crore for Q2 FY2026, marking a 2.44% increase from INR 3,462.40 crore in Q2 FY2025. However, the net profit for the quarter stood at INR 312.49 crore, down by 7.79% compared to INR 338.89 crore in the same quarter of the previous year.

For the half-year period ending September 30, 2025, Bafna Pharmaceuticals achieved a total revenue of INR 7,009.22 crore, with a net profit of INR 651.38 crore.

Key Financial Metrics

Particulars (INR in crore)	Q2 FY2026	Q2 FY2025	% Change
Revenue from Operations	3,546.82	3,462.40	+2.44%
Net Profit	312.49	338.89	-7.79%
Earnings per Share (INR)	1.32	1.43	-7.69%

Balance Sheet Strength

The company's financial position shows improvement, with total assets increasing to INR 16,068.27 crore as of September 30, 2025, up from INR 13,215.84 crore in the previous year, indicating a 21.58% growth.

Operational Performance

Despite the slight dip in quarterly profits, Bafna Pharmaceuticals demonstrated resilience in its operations. The company's Board of Directors approved these results in a meeting held on November 11, 2025, as recommended by the Audit Committee.

Auditor's Observations

The independent auditor's review report highlighted two key matters:

Outstanding foreign currency receivables of INR 213 crore as of September 30, 2025, which exceed the time limit stipulated by RBI regulations.
An income tax refund adjustment of INR 45.17 crore from previous assessment years, currently under legal proceedings.

The company's management is addressing these issues, with efforts underway to obtain necessary approvals and resolve the tax matter through a writ petition filed with the Madras High Court.

Market Position

While specific market share data was not provided, the steady revenue growth suggests that Bafna Pharmaceuticals is maintaining its position in the competitive pharmaceutical sector. The company continues to focus on its core business of manufacturing pharmaceutical formulations.

Looking Ahead

As Bafna Pharmaceuticals navigates through the evolving pharmaceutical landscape, investors and stakeholders will be keen to see how the company addresses the challenges highlighted in the auditor's report and leverages its increased asset base to drive future growth and profitability.

The company's ability to maintain revenue growth in a challenging environment is noteworthy, and future quarters will be crucial in determining if this trend can translate into improved bottom-line performance.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+4.32%	+19.57%	+4.96%	+123.76%	+114.99%	-0.06%

Bafna Pharmaceuticals Limited , a prominent player in the pharmaceutical industry, has reported robust financial results for the first quarter ended June 30, 2025, alongside significant corporate announcements.

Financial Performance

The company's unaudited financial results for Q1 FY2026 showcase a notable improvement in both revenue and profitability:

Particulars (INR in Lakhs)	Q1 FY2026	Q1 FY2025	YoY Change
Revenue from Operations	3462.40	3328.63	+4.02%
Total Income	3521.96	3379.16	+4.23%
Net Profit	338.89	(72.36)	-
Total Comprehensive Income	334.27	(71.45)	-

Bafna Pharmaceuticals demonstrated a strong turnaround, with a net profit of ₹338.89 lakhs in Q1 FY2026, compared to a loss of ₹72.36 lakhs in the same quarter last year. The company's revenue from operations increased by 4.02% year-over-year to ₹3,462.40 lakhs.

Corporate Developments

The Board of Directors, in their meeting held on August 12, 2025, made several key announcements:

Annual General Meeting and Related Matters

The 30th Annual General Meeting (AGM) is scheduled for September 19, 2025, to be held through video conferencing.
The Register of Members and Share Transfer Books will remain closed from September 13-19, 2025.
The cut-off date for determining voting eligibility for the AGM is set as September 12, 2025.

Leadership Changes

The Board approved the re-appointment of two Independent Directors and the CEO:

Mrs. Ravichandran Chitra: Re-appointed as Non-Executive Independent Director for a second term of five years, effective November 12, 2025.
Mr. Palamadai Krishnan Sundaresan: Re-appointed as Non-Executive Independent Director for a second term of five years, effective September 19, 2025.
Mr. Bafna Mahaveer Chand: Re-appointed as Chief Executive Officer for a further term of five years, effective September 10, 2025.

Committee Reconstitution

The Nomination and Remuneration Committee has been reconstituted with:

Mr. Navin Kumar as Chairman
Mrs. Ravichandran Chitra and Mrs. Akila Chintalapati Raju as members

Other Noteworthy Developments

The company achieved the prescribed Minimum Public Shareholding as of April 2, 2025.
The sale of assets from the Madhavaram manufacturing unit was completed during the quarter.

These results and corporate actions reflect Bafna Pharmaceuticals' strong performance and strategic moves aimed at strengthening its leadership and governance structure. The significant improvement in profitability and the reappointment of key leaders signal the company's focus on sustainable growth and operational excellence in the pharmaceutical sector.